ArticleInternational archives of otorhinolaryngology2026
Efficacy of
Article in International archives of otorhinolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lactococcus lactis (L. lactis) is widely used in fermented foods and has immunomodulatory properties. However, its effects on allergic rhinitis remain unclear. Objective: This study evaluated the efficacy of L. lactis 11/19-B1 in mitigating allergic rhinitis symptoms in a mouse model. Methods: Female BALB/c mice were fed a diet supplemented with heat-killed L. lactis 11/19-B1, while allergic rhinitis was induced via intraperitoneal and intranasal administration of ovalbumin (OVA). The positive control group received a standard diet without L. lactis 11/19-B1. Sneezing frequency was recorded, and tissue samples were collected for analysis. Serum OVA-immunoglobulin E (IgE) levels were also measured, nasal mucosa histopathology assessed, and the interleukin 4 (IL-4), interferon gamma (IFN-γ), T helper (Th) 1/Th2 balance in cluster of differentiation (CD) 4+ T cells analyzed by flow cytometry (FCM). Results: Mice receiving L. lactis 11/19-B1 showed significantly reduced sneezing frequency and decreased eosinophil infiltration in the nasal mucosa. No significant changes in serum OVA-IgE levels were observed. Flow cytometry analysis showed a significant increase in the Th1/Th2 ratio in Peyer's patches in the L. lactis 11/19-B1 group compared with the positive control group. Conclusion: These findings suggest that L. lactis 11/19-B1 alleviates allergic rhinitis symptoms by modulating the Th1/Th2 balance and reducing eosinophil infiltration, independently of IgE suppression. These findings highlight its potential as a dietary supplement for allergic disease management .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.